Novel Nasal Spray Improves Symptoms in Patients with Treatment-Resistant Depression

A new nasal spray therapy showed rapid improvement in patients with treatment-resistant depression, according to recent data from two phase 3 clinical trials.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive findings from their latest data on the use of esketamine nasal spray to improve depressive symptoms in patients who had not responded to 2 or more currently available antidepressants. Esketamine nasal spray, a non-competitive N-methyl-D-aspartate receptor agonist, is an investigational compound thought to help restore synaptic connections in brain cells in patients with major depressive disorder.

According to the press release, the results demonstrated the potential of the treatment to address a significant unmet need for more than 30% of individuals with treatment-resistant major depressive disorder.

In the first study, flexibly-dosed esketamine nasal spray plus a newly initiated oral antidepressant demonstrated a statistically significant, clinically meaningful, rapid reduction of depressive symptoms compared with a placebo plus an oral antidepressant.

Treatment-resistant was defined as patients who had not responded to 2 or more currently available antidepressants of adequate dose and duration in the current episode of depression.

The study enrolled adults with moderate-to-severe, non-psychotic, recurrent or persistent depression, and a history of treatment resistance. Those with treatment-resistant depression were randomized to receive flexibly-dosed esketamine nasal spray (56 or 84 mg twice weekly).

In the second study, esketamine was evaluated in patients aged 65 years and older with treatment-resistant depression. To improve tolerability, patients were given a lower starting dose (28 mg) of esketamine nasal spray (flexibly dosed as 28 mg, 56 mg, or 84 mg) plus a newly initiated oral antidepressant or placebo nasal spray, plus a newly initiated oral antidepressant.

However, the study narrowly missed statistical significance for its primary efficacy endpoint.

“The positive phase 3 results for esketamine nasal spray in adults with treatment-resistant depression are exciting, particularly as they mark the first time an antidepressant has achieved superiority versus an active comparator in any clinical trial for major depressive disorder,” Husseini K. Manji, MD, global head of Janssen Research & Development’s neuroscience therapeutic area, said in the press release.

“What makes this even more significant is that the response was rapid and this milestone was achieved in patients deemed to be treatment-resistant. We are also pleased with the clinically meaningful outcomes for esketamine nasal spray in elderly patients, a population that often has greater disability and lower response rates.”

Reference

New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression [news release]. Janssen’s website. http://www.janssen.com/new-phase-3-data-show-esketamine-nasal-spray-demonstrated-rapid-improvements-depressive-symptoms. Accessed May 14, 2018.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Midazolam Nasal Spray—from global biopharmaceutical company UCB, Brussels, Belgium (UCB)—has been previously granted Orphan Drug and Fast Track designations by the FDA
Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg) offers a new treatment option to adults living with HIV.
Two studies assessed prostate specific antigen (PSA) progression in patients treated with apalutamide (Erleada, Janssen) and the association between PSA doubling time and survival.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$